Literature DB >> 20621636

Expression and characterization of Mycobacterium tuberculosis CYP144: common themes and lessons learned in the M. tuberculosis P450 enzyme family.

Max D Driscoll1, Kirsty J McLean, Myles R Cheesman, Thomas A Jowitt, Marjorie Howard, Paul Carroll, Tanya Parish, Andrew W Munro.   

Abstract

CYP144 from Mycobacterium tuberculosis was expressed and purified. CYP144 demonstrates heme thiolate coordination in its ferric form, but the cysteinate is protonated to thiol in both the carbon monoxide-bound and ligand-free ferrous forms (forming P420 in the former). Tight binding of various azole drugs was shown, with affinity for miconazole (K(d)=0.98 μM), clotrimazole (0.37 μM) and econazole (0.78 μM) being highest. These azoles are also the trio with the highest affinity for the essential CYP121 and for the cholesterol oxidase CYP125 (essential for host infection), and have high potency as anti-mycobacterial drugs. Construction of a Mtb gene knockout strain demonstrated that CYP144 is not essential for growth in vitro. However the deletion strain was more sensitive to azole inhibition in culture suggesting an important role for CYP144 in cell physiology and/or in mediating azole resistance. The biophysical and genetic features of CYP144 are compared to those of other characterized Mtb P450s, identifying both commonality in properties (including thiolate protonation in ferrous P450s) and intriguing differences in thermodynamic and spectroscopic features. Our developing knowledge of the Mtb P450s has revealed unusual biochemistry and gene essentiality, highlighting their potential as drug targets in this human pathogen.
Copyright © 2010. Published by Elsevier B.V.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20621636     DOI: 10.1016/j.bbapap.2010.05.015

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  12 in total

Review 1.  Spectroscopic studies of the cytochrome P450 reaction mechanisms.

Authors:  Piotr J Mak; Ilia G Denisov
Journal:  Biochim Biophys Acta Proteins Proteom       Date:  2017-06-28       Impact factor: 3.036

Review 2.  Pathogen roid rage: cholesterol utilization by Mycobacterium tuberculosis.

Authors:  Matthew F Wipperman; Nicole S Sampson; Suzanne T Thomas
Journal:  Crit Rev Biochem Mol Biol       Date:  2014-03-10       Impact factor: 8.250

Review 3.  Cholesterol catabolism as a therapeutic target in Mycobacterium tuberculosis.

Authors:  Hugues Ouellet; Jonathan B Johnston; Paul R Ortiz de Montellano
Journal:  Trends Microbiol       Date:  2011-09-15       Impact factor: 17.079

Review 4.  Potential drug targets in the Mycobacterium tuberculosis cytochrome P450 system.

Authors:  Paul R Ortiz de Montellano
Journal:  J Inorg Biochem       Date:  2018-01-12       Impact factor: 4.155

5.  Domain-Swap Dimerization of Acanthamoeba castellanii CYP51 and a Unique Mechanism of Inactivation by Isavuconazole.

Authors:  Vandna Sharma; Brian Shing; Lilian Hernandez-Alvarez; Anjan Debnath; Larissa M Podust
Journal:  Mol Pharmacol       Date:  2020-10-02       Impact factor: 4.436

6.  Fragment-Based Approaches to the Development of Mycobacterium tuberculosis CYP121 Inhibitors.

Authors:  Madeline E Kavanagh; Anthony G Coyne; Kirsty J McLean; Guy G James; Colin W Levy; Leonardo B Marino; Luiz Pedro S de Carvalho; Daniel S H Chan; Sean A Hudson; Sachin Surade; David Leys; Andrew W Munro; Chris Abell
Journal:  J Med Chem       Date:  2016-03-22       Impact factor: 7.446

7.  Deletion of cyp125 Confers Increased Sensitivity to Azoles in Mycobacterium tuberculosis.

Authors:  Paul Carroll; Tanya Parish
Journal:  PLoS One       Date:  2015-07-21       Impact factor: 3.240

8.  Imidazoles Induce Reactive Oxygen Species in Mycobacterium tuberculosis Which Is Not Associated with Cell Death.

Authors:  Heather A Howell Wescott; David M Roberts; Christian L Allebach; Rachel Kokoczka; Tanya Parish
Journal:  ACS Omega       Date:  2017-01-05

9.  Structural Characterization and Ligand/Inhibitor Identification Provide Functional Insights into the Mycobacterium tuberculosis Cytochrome P450 CYP126A1.

Authors:  Jude T Chenge; Le Van Duyet; Shalini Swami; Kirsty J McLean; Madeline E Kavanagh; Anthony G Coyne; Stephen E J Rigby; Myles R Cheesman; Hazel M Girvan; Colin W Levy; Bernd Rupp; Jens P von Kries; Chris Abell; David Leys; Andrew W Munro
Journal:  J Biol Chem       Date:  2016-12-08       Impact factor: 5.157

10.  Structural characterization of CYP144A1 - a cytochrome P450 enzyme expressed from alternative transcripts in Mycobacterium tuberculosis.

Authors:  Jude Chenge; Madeline E Kavanagh; Max D Driscoll; Kirsty J McLean; Douglas B Young; Teresa Cortes; Dijana Matak-Vinkovic; Colin W Levy; Stephen E J Rigby; David Leys; Chris Abell; Andrew W Munro
Journal:  Sci Rep       Date:  2016-05-26       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.